Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes

This study aimed to evaluate the real-world cardiovascular outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with atherosclerotic cardiovascular disease (ASCVD) and obesity without diabetes. The findings indicated that GLP-1 RA use was associated with reduced all-cause mortality, acute myocardial infarction, and heart failure hospitalization, aligning with results from the SELECT trial, although no significant effect on stroke was observed. The authors emphasize that while their observational data support the benefits of GLP-1 RAs, causal conclusions cannot be drawn.